Who are Effexor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pristiq, Duloxetine (Cymbalta), Treatment (Viibryd), toludesvenlafaxine hydrochloride sustained-release tablets, desvenlafaxine succinate sustained release, Dulox capsule (60mg).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/effexor-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Effexor — Competitive Intelligence Brief

Effexor (Venlafaxine Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Area: Metabolic.

marketed Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Effexor (Venlafaxine Hydrochloride) — Pfizer. Potentiates serotonin and norepinephrine in CNS through reuptake inhibition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Effexor TARGET	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Duloxetine (Cymbalta)	Duloxetine (Cymbalta)	New York State Psychiatric Institute	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Treatment (Viibryd)	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)
toludesvenlafaxine hydrochloride sustained-release tablets	toludesvenlafaxine hydrochloride sustained-release tablets	Shanghai Mental Health Center	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
desvenlafaxine succinate sustained release	desvenlafaxine succinate sustained release	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Dulox capsule (60mg)	Dulox capsule (60mg)	Ain Shams University	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Effexor — Competitive Intelligence Brief. https://druglandscape.com/ci/effexor-xr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab